Posted 19 October 2026
Researchers at UCLA’s David Geffen School of Medicine completed a scoping review in PubMed of six peptide supplements (BPC-157, TB-500, CJC-1295, MK-677 [ibutamoren], ipamorelin, and GHK-Cu) combined with types of musculoskeletal tissue as search terms and found:
- 67% of identified publications utilized preclinical animal models, most commonly in rats; findings were inconsistent.
- Human clinical studies lacked robust controls or rigorous study designs and yielded mixed results and modest improvements at best.
- Significant risks of MK-677 include insulin resistance, congestive heart failure, and metabolic dysfunction.
The researchers concluded:
Overall, emerging peptide supplements lack clear evidence to support long-term safety or clinical efficacy for musculoskeletal health. Until more robust clinically relevant data are available, these supplements cannot be recommended as a replacement for or adjunct to established standards of care, and clinicians should counsel patients accordingly.
Reference: Tewari K. Liu TP. Im C. and others. Peptide supplements and … Read the rest